Hepatocellular carcinoma in thalassaemia: An update of the Italian Registry

British Journal of Haematology

Volumn 167, Issue 1, 2014, Pages 121-126

  Borgna Pignatti, Caterina ^a   Garani, Maria Chiara ^a   Forni, Gian Luca ^b   Cappellini, Maria Domenica ^c   Cassinerio, Elena ^c   Fidone, Carmelo ^d   Spadola, Vincenzo ^d   Maggio, Aurelio ^e   Restivo Pantalone, Gaetano ^e   Piga, Antonio ^f   Longo, Filomena ^f   Gamberini, Maria Rita ^g   Ricchi, Paolo ^h   Costantini, Silvia ⁱ   D'Ascola, Domenico ^j   Cianciulli, Paolo ^k   Lai, Maria Eliana ^l   Carta, Maria Paola ^l   Ciancio, Angela ^m   Cavalli, Paola ⁿ   Putti, Maria Caterina ^o   Barella, Susanna ^p   Amendola, Giovanni ^q   Campisi, Saveria ^r   Capra, Marcello ^r   Caruso, Vincenzo ^s   Colletta, Grazia ^a   Volpato, Stefano ^a   more..

^a UNIVERSITY OF FERRARA   (Italy)

^b GALLIERA HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d Ospedale Civile   (Italy)

^e PO G di Cristina   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^h CARDARELLI HOSPITAL   (Italy)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^k S EUGENIO HOSPITAL   (Italy)

^l UNIVERSITY OF CAGLIARI   (Italy)

^m Ospedale Civile di Matera   (Italy)

ⁿ Ospedale di Lecce   (Italy)

^o UNIVERSITY OF PADOVA   (Italy)

^p Osp Regionale per le Microcitemie   (Italy)

^q Ospedale Umberto I   (Italy)

^r Di Cristina   (Italy)

^s GARIBALDI HOSPITAL   (Italy)

more..

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Iron overload; Liver; Thalassaemia

Indexed keywords

DEFEROXAMINE; FERRITIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C ANTIBODY; INTERFERON; IRON; IRON CHELATING AGENT; RIBAVIRIN; SORAFENIB; VIRUS RNA;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CHELATION THERAPY; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; DRY WEIGHT; EARLY DIAGNOSIS; ECHOGRAPHY; FEMALE; HEALTH CARE FACILITY; HEMOSIDEROSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; ITALY; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER LEVEL; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENINGOCOCCEMIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SICKLE CELL BETA THALASSEMIA; THALASSEMIA; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; UNSPECIFIED SIDE EFFECT; VOLUNTARY REPORTING; BLOOD; CARCINOMA, HEPATOCELLULAR; COMORBIDITY; COMPLICATION; KAPLAN MEIER METHOD; LIVER; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PREVALENCE; REGISTER; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; COMORBIDITY; FEMALE; FERRITINS; HUMANS; IRON; ITALY; KAPLAN-MEIER ESTIMATE; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREVALENCE; REGISTRIES; THALASSEMIA; TREATMENT OUTCOME;

EID: 84911008692     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13009     Document Type: Article

References (29)

1. Ansari, S., Azarkivan, A. & Halagi, F. (2013) Incidence of hepatocellular carcinoma in patients with thalassaemia who had hepatitis C. Acta Medica Iranica, 51, 404-407.
2. Asahina, Y., Tsuchiya, K., Nishimura, T., Muraoka, M., Suzuki, Y., Tamaki, N., Yasui, Y., Hosokawa, T., Ueda, K., Nakanishi, H., Itakura, J., Takahashi, Y., Kurosaki, M., Enomoto, N., Nakagawa, M., Kakinuma, S., Watanabe, M. & Izumi, N. (2013) α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology (Baltimore, MD), 58, 1253-1262.
3. Borgna-Pignatti, C., De Stefano, P., Sessa, F. & Avato, F. (1986) Hepatocellular carcinoma in thalassaemia major. Medical and Pediatric Oncology, 14, 327-328.
4. Borgna-Pignatti, C., Vergine, G., Lombardo, T., Cappellini, M.D., Cianciulli, P., Maggio, A., Renda, D., Lai, M.E., Mandas, A., Forni, G., Piga, A. & Bisconte, M.G. (2004a) Hepatocellular carcinoma in the thalassaemia syndromes. British Journal of Haematology, 124, 114-117.
5. Borgna-Pignatti, C., Rugolotto, S., De Stefano, P., Zhao, H., Cappellini, M.D., Del Vecchio, G.C., Romeo, M.A., Forni, G.L., Gamberini, M.R., Ghilardi, R., Piga, A. & Cnaan, A. (2004b) Survival and complications in patients with thalassaemia major treated with transfusion and deferoxamine. Haematologica, 89, 1187-1193.
6. Cabibbo, G., Maida, M., Genco, C., Antonucci, M. & Cammà, C. (2012) Causes of and prevention strategies for hepatocellular carcinoma. Seminars in Oncology, 39, 374-383.
7. Christofidou, M., Lambropoulou-Karatza, C., Dimitracopoulos, G. & Spiliopoulou, I. (2000) Distribution of hepatitis C virus genotypes in viremic patients with beta-thalassaemia. European Journal of Clinical Microbiology & Infectious Diseases, 19, 728-730.
8. Colombo, M., Raoul, J.-L., Lencioni, R., Galle, P.R., Zucman-Rossi, J., Bañares, R., Seehofer, D., Neuhaus, P. & Johnson, P. (2013) Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. European Journal of Gastroenterology & Hepatology, 25, 639-651.
9. Di Marco, V., Capra, M., Angelucci, E., Borgna-Pignatti, C., Telfer, P., Harmatz, P., Kattamis, A., Prossamariti, L., Filosa, A., Rund, D., Gamberini, M.R., Cianciulli, P., De Montalembert, M., Gagliardotto, F., Foster, G., Grangè, J.D., Cassarà, F., Iacono, A., Cappellini, M.D., Brittenham, G.M., Iacono, A., Cappellini, M.D., Brittenham, G.M., Prati, D., Pietrangelo, A., Craxì, A., Maggio, A. & Italian Society for the Study of Thalassemia and Haemoglobinopathies; Italian Association for the Study of the Liver (2010a) Management of chronic viral hepatitis in patients with thalassaemia: recommendations from an international panel. Blood, 116, 2875-2883.
10. Di Marco, V., Bronte, F., Cabibi, D., Calvaruso, V., Alaimo, G., Borsellino, Z., Gagliardotto, F., Almasio, P.L., Capra, M. & Craxì, A. (2010b) Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. British Journal of Haematology, 148, 476-479.
11. Fragatou, S., Tsourveloudis, I. & Manesis, G. (2010) Incidence of hepatocellular carcinoma in a thalassaemia unit. Hemoglobin, 34, 221-226.
12. Gerlich, W.H. (2013) Medical virology of hepatitis B: how it began and where we are now. Virology Journal, 10, 239.
13. Hung, C.-H., Lu, S.-N., Wang, J.-H., Hu, T.-H., Chen, C.-H., Huang, C.-M. & Lee, C.-M. (2011) Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients. Antiviral Therapy, 16, 959-968.
14. Izumi, N., Asahina, Y., Kurosaki, M., Yamada, G., Kawai, T., Kajiwara, E., Okamura, Y., Takeuchi, T., Yokosuka, O., Kariyama, K., Toyoda, J., Inao, M., Tanaka, E., Moriwaki, H., Adachi, H., Katsushima, S., Kudo, M., Takaguchi, K., Hiasa, Y., Chayama, K., Yatsuhashi, H., Oketani, M. & Kumada, H. (2013) Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. Journal of Gastroenterology, 48, 382-390.
15. Ladis, V., Chouliaras, G., Berdoukas, V., Chatziliami, A., Fragodimitri, C., Karabatsos, F., Youssef, J., Kattamis, A. & Karagiorga-Lagana, M. (2011) Survival in a large cohort of Greek patients with transfusion-dependent beta thalassaemia and mortality ratios compared to the general population. European Journal of Haematology, 86, 332-338.
16. Lee, M.-H., Yang, H.-I., Lu, S.-N., Jen, C.-L., You, S.-L., Wang, L.-Y., L'italien, G., Chen, C.-J. & Yuan, Y. (2014) Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. International Journal of Cancer, 135, 1119-1126.
17. Llovet, J.M., Ducreux, M., Lencioni, R., Di Bisceglie, A.M., Galle, P.R., Dufour, J.F., Greten, T.F., Raymond, E., Roskams, T., De Baere, T., Ducreux, M., Mazzaferro, V., Bernardi, M., Bruix, J., Colombo, M. & Zhu, A. (2012) for the European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology, 56, 908-943.
18. Maakaron, J.E., Cappellini, M.D., Graziadei, G., Ayache, J.B. & Taher, A.T. (2013) Hepatocellular carcinoma in hepatitis-negative patients with thalassaemia intermedia: a closer look at the role of siderosis. Annals of Hepatology, 12, 142-146.
19. Makiyama, A., Itoh, Y., Kasahara, A., Imai, Y., Kawata, S., Yoshioka, K., Tsubouchi, H., Kiyosawa, K., Kakumu, S., Okita, K., Hayashi, N. & Okanoue, T. (2004) Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer, 101, 1616-1622.
20. Mancuso, A., Sciarrino, E., Renda, M.C. & Maggio, A. (2006) A prospective study of hepatocellular carcinoma incidence in thalassaemia. Hemoglobin, 30, 119-124.
21. Mirmomen, S., Alavian, S.-M., Hajarizadeh, B., Kafaee, J., Yektaparast, B., Zahedi, M.-J., Zand, V., Azami, A.-A., Hosseini, M.M.-A., Faridi, A.-R., Davari, K. & Hajibeigi, B. (2006) Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infecions in patients with beta-thalassaemia in Iran: a multicenter study. Archives of Iranian Medicine, 9, 319-323.
22. Prati, D., Zanella, A., Farma, E., De Mattei, C., Bosoni, P., Zappa, M., Picone, A., Mozzi, F., Rebulla, P., Cappellini, M.D., Allain, J.P. & Sirchia, G. (1998) A multicenter prospective study on the risk of acquiring liver disease in anti-hepatitis C virus negative patients affected from homozygous beta-thalassaemia. Blood, 92, 3460-3464.
23. Restivo Pantalone, G., Renda, D., Valenza, F., D'Amato, F., Vitrano, A., Cassarà, F., Rigano, P., Di Salvo, V., Giangreco, A., Bevacqua, E. & Maggio, A. (2010) Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience. British Journal of Haematology, 150, 245-247.
24. Samimi-Rad, K. & Shahbaz, B. (2007) Hepatitis C virus genotypes among patients with thalassaemia and inherited bleeding disorders in Markazi province, Iran. Haemophilia, 13, 156-163.
25. Shiratori, Y., Ito, Y., Yokosuka, O., Imazeki, F., Nakata, R., Tanaka, N., Arakawa, Y., Hashimoto, E., Hirota, K., Yoshida, H., Ohashi, Y. & Omata, M. (2005) Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Annals of Internal Medicine, 142, 105-114.
26. Telfer, P.T., Warburton, F., Christou, S., Hadjigavriel, M., Sitarou, M., Kolnagou, A. & Angastiniotis, M. (2009) Improved survival in thalassaemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica, 94, 1777-1778.
27. Vento, S., Cainelli, F. & Cesario, F. (2006) Infections and thalassaemia. The Lancet Infectious Diseases, 6, 226-233.
28. Wonke, B., Hoffbrand, A.V., Brown, D. & Dusheiko, G. (1990) Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major. Journal of Clinical Pathology, 43, 638-640.
29. Wood, J.C., Enriquez, C., Ghugre, N., Tyzka, J.M., Carson, S., Nelson, M.D. & Coates, T.D. (2005) MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassaemia and sickle cell disease patients. Blood, 106, 1460-1465.